

# Anisur Rahman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8304417/anisur-rahman-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

9,003  
citations

40  
h-index

93  
g-index

196  
ext. papers

10,853  
ext. citations

5.2  
avg, IF

5.77  
L-index

#	Paper	IF	Citations
154	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
153	Systemic lupus erythematosus. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 929-39	59.2	1367
152	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
151	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
150	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
149	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 917-30	13.6	186
148	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175
147	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. <i>Rheumatology</i> , <b>2009</b> , 48, 673-5	3.9	160
146	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , <b>2011</b> , 50, 982-8	3.9	120
145	Systemic lupus erythematosus. <i>Orphanet Journal of Rare Diseases</i> , <b>2006</b> , 1, 6	4.2	120
144	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
143	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 280-90		115
142	Effective delivery styles and content for self-management interventions for chronic musculoskeletal pain: a systematic literature review. <i>Clinical Journal of Pain</i> , <b>2012</b> , 28, 344-54	3.5	99
141	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R154	5.7	88
140	Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 845-54		88
139	Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 153-9	13.6	87
138	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen $\beta$ -glycoprotein I. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 2774-82		84

137	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , <b>2010</b> , 49, 1665-9	3.9	84
136	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
135	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 892-9		81
134	Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 866-70		78
133	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
132	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 4113-9		76
131	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , <b>2009</b> , 48, 691-5	3.9	74
130	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
129	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
128	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 322-9	4.1	65
127	Fibromyalgia. <i>BMJ, The</i> , <b>2014</b> , 348, g1224	5.9	64
126	Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs. <i>European Journal of Pain</i> , <b>2011</b> , 15, 775.e1-11	3.7	59
125	Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. <i>Journal of Immunology</i> , <b>2010</b> , 184, 6622-8	5.3	58
124	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
123	Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 55, 352-367	12.3	51
122	How do antiphospholipid antibodies bind beta2-glycoprotein I?. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 2111-21		50
121	Measuring IgA Anti- $\beta$ -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156407	3.7	50
120	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of $\beta$ -glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , <b>2015</b> , 54, 722-7	3.9	49

119	"It struck me that they didn't understand pain": the specialist pain clinic experience of patients with chronic musculoskeletal pain. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 691-6		48
118	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , <b>2018</b> , 57, 470-479	4.7	47
117	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
116	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1167-76	4.7	43
115	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , <b>2020</b> , 39, 100610	11.1	42
114	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1505-13	4.7	38
113	Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151245	3.7	37
112	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
111	Systematic analysis of sequences of anti-DNA antibodies--relevance to theories of origin and pathogenicity. <i>Lupus</i> , <b>2002</b> , 11, 807-23	2.6	36
110	Antibodies to domain I of $\beta$ 2-glycoprotein I and IgA antiphospholipid antibodies in patients with $\beta$ 2-negative antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 317-9	2.4	35
109	Atherosclerosis in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2017</b> , 31, 364-372	5.3	34
108	Novel Three-Day, Community-Based, Nonpharmacological Group Intervention for Chronic Musculoskeletal Pain (COPERS): A Randomised Clinical Trial. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002040	11.6	34
107	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , <b>2009</b> , 48, 1548-52	3.9	31
106	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31
105	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. <i>BMC Biotechnology</i> , <b>2006</b> , 6, 8	3.5	30
104	A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. <i>Seminars in Arthritis and Rheumatism</i> , <b>2003</b> , 32, 246-65	5.3	30
103	Anti-DNA antibodies--overview of assays and clinical correlations. <i>Lupus</i> , <b>2002</b> , 11, 770-3	2.6	29
102	The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. <i>Journal of Molecular Biology</i> , <b>2001</b> , 307, 149-60	6.5	29

101	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , <b>2016</b> , 1,	28	28
100	Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. <i>BMJ Open</i> , <b>2018</b> , 8, e019491	3	28
99	PEGylated drugs in rheumatology--why develop them and do they work?. <i>Rheumatology</i> , <b>2014</b> , 53, 391-63.9		27
98	Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1729-36	5.3	27
97	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , <b>2020</b> , 29, 1571-1593	2.6	27
96	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
95	Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 141-54	5.3	26
94	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. <i>Molecular Immunology</i> , <b>2003</b> , 40, 49-60	4.3	25
93	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
92	Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. <i>Molecular Immunology</i> , <b>2002</b> , 39, 299-311	4.3	23
91	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2009</b> , 48, 573-5	3.9	21
90	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
89	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 26	5.7	20
88	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
87	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , <b>2016</b> , 55, 1243-50	3.9	19
86	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 98-103	4.7	18
85	Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course. <i>BMJ Open</i> , <b>2013</b> , 3, e003534	3	18
84	Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. <i>Journal of Immunology</i> , <b>2009</b> , 182, 4836-43	5.3	18

83	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
82	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
81	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. <i>Arthritis Research</i> , <b>2005</b> , 7, R47-56		17
80	Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 35129-36	5.4	17
79	Imaging assessment of cardiovascular disease in systemic lupus erythematosus. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 694143		16
78	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report <b>2017</b> , 317-338		16
77	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
76	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. <i>Molecular Immunology</i> , <b>2004</b> , 40, 745-58	4.3	15
75	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
74	Important determinants of self-efficacy in patients with chronic musculoskeletal pain. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 1187-92	4.1	15
73	A critical analysis of the tools to evaluate neuropsychiatric lupus. <i>Lupus</i> , <b>2017</b> , 26, 504-509	2.6	14
72	Evaluating the conformation of recombinant domain I of (D)-glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , <b>2011</b> , 49, 56-63	4.3	14
71	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <i>BMJ Open</i> , <b>2019</b> , 9, e028697		13
70	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e2549	9.8	13
69	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , <b>2018</b> , 93, 114-123	15.5	13
68	Efficacy of an out-patient pain management programme for people with joint hypermobility syndrome. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1665-9	3.9	13
67	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. <i>Arthritis Research and Therapy</i> , <b>2005</b> , 7, R971-83	5.7	13
66	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13

65	The association between IgG and IgM antibodies against cardiolipin, $\beta$ -glycoprotein I and Domain I of $\beta$ -glycoprotein I with disease profile in patients with multiple sclerosis. <i>Molecular Immunology</i> , <b>2016</b> , 75, 161-7	4.3	12
64	Effectiveness and cost-effectiveness of a novel, group self-management course for adults with chronic musculoskeletal pain: study protocol for a multicentre, randomised controlled trial (COPERS). <i>BMJ Open</i> , <b>2013</b> , 3,	3	12
63	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 47	5.7	11
62	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3512-21		11
61	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 2392-401		11
60	Improving the self-management of chronic pain: COping with persistent Pain, Effectiveness Research in Self-management (COPERS). <i>Programme Grants for Applied Research</i> , <b>2016</b> , 4, 1-440	1.5	11
59	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
58	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
57	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. <i>Rheumatology</i> , <b>2020</b> , 59, 524-533	3.9	10
56	Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 71-2	8.1	9
55	Oxidation of $\beta$ -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186513	3.7	8
54	New therapeutic avenues in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2015</b> , 29, 794-809	5.3	8
53	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2413	8.4	8
52	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. <i>Rheumatology Advances in Practice</i> , <b>2018</b> , 2, rky003	1.1	8
51	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2244	8.4	8
50	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
49	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
48	Molecular expression systems for anti-DNA antibodies--1. <i>Lupus</i> , <b>2002</b> , 11, 824-32	2.6	7

47	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
46	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
45	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. <i>BMC Biotechnology</i> , <b>2015</b> , 15, 104	3.5	6
44	Anti-DNA antibodies--structure and function. <i>Lupus</i> , <b>2002</b> , 11, 776-9	2.6	6
43	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 1446-1458	9.4	6
42	Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 957-967	5.1	6
41	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , <b>2020</b> , 59, 146-152	3.9	6
40	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
39	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by IgG From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , <b>2017</b> , 7, 10788	4.9	5
38	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000013	4.6	5
37	Origin and structure of autoantibodies and antigens in autoimmune rheumatic diseases. <i>Lupus</i> , <b>2008</b> , 17, 232-5	2.6	5
36	Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol. <i>BMJ Open</i> , <b>2019</b> , 9, e028937	3	5
35	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
34	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5
33	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, R48	5.7	4
32	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
31	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
30	The role of in vitro expression systems in the investigation of antibodies to DNA. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 130-9	5.3	3



29	Structure-function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. <i>Expert Reviews in Molecular Medicine</i> , <b>1999</b> , 1999, 1-28	6.7	3
28	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis <b>2017</b> , 77-116		3
27	Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. <i>Rheumatology</i> , <b>2020</b> , 59, 3314-3323	3.9	3
26	Red cell distribution width correlates with fatigue levels in a diverse group of patients with systemic lupus erythematosus irrespective of anaemia status. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 852-854	2.2	3
25	Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. <i>Lupus</i> , <b>2019</b> , 28, 916-917	2.6	2
24	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 3262-3267	3.9	2
23	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
22	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. <i>Scientific Reports</i> , <b>2020</b> , 10, 3102	4.9	2
21	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. <i>Current Rheumatology Reviews</i> , <b>2008</b> , 4, 2-11	1.6	2
20	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies <b>2006</b> , 470-491		2
19	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests <b>2017</b> , 171-187		2
18	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
17	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
16	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
15	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. <i>Scientific Reports</i> , <b>2021</b> , 11, 4542	4.9	2
14	Domain I of $\beta$ 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. <i>Lupus</i> , <b>2019</b> , 28, 893-897	2.6	1
13	140 Evaluating the prevalence of iron deficiency and anaemia in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2018</b> , 57,	3.9	1
12	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , <b>2017</b> , 56, 1041-1043	3.9	1

11	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 287	5.7	1
10	Structure and function of autoantibodies and their role in autoimmune rheumatic diseases. <i>Expert Review of Clinical Immunology</i> , <b>2006</b> , 2, 225-36	5.1	1
9	132 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. <i>Rheumatology</i> , <b>2018</b> , 57,	3.9	1
8	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes <b>2019</b> , 355-365		0
7	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 4185-4198	3.9	0
6	Managing conventional cardiovascular risk factors in the lupus clinic - what can we achieve?. <i>Lupus</i> , <b>2018</b> , 27, 172-173	2.6	
5	The research that time forgot. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2013</b> , 74, 702-3	0.8	
4	Do high-sensitivity C-reactive protein levels help predict risk of cardiovascular disease in patients with osteoarthritis?. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 122-3		
3	Antiphospholipid syndrome and pregnancy. <i>British Journal of Midwifery</i> , <b>2021</b> , 29, 308-309	0.3	
2	Antilipoprotein and Antiendothelial Cell Antibodies <b>2019</b> , 375-376		
1	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 842923	8.4	